March 2nd, 2010, by Digital Davo | clinical trials
Department of Dermatology, New York Presbyterian Hospital at Columbia University The Clinical Research Unit is seeking men and women, at least 18 years old, to participate in a research study of a new oral investigational treatment for Rosacea. The study requires 10 visits over 16 weeks. Participants may be eligible to receive: Free facial skin examinations …
January 12th, 2010, by Digital Davo | clinical trials
The first time you hear of a new drug, you probably ask – what is it ? Well are you ready for a marketing mouthful – “Apremilast is a novel, orally available small molecule compound that exhibits anti-inflammatory activities through the suppression of multiple pro-inflammatory mediators including, TNF-alpha, interleukins 6, 17 & 23, and interferon-gamma among others.” Apremilast (CC-10004) has been trialled for …
November 20th, 2009, by Digital Davo | clinical trials, metrogel, topicals
The Clinical Trials register has listed a just completed trial for something cryptically called 0444 Gel. The Gel is targeted for the papules and pustules of rosacea. Apparently the study started in January 2008 and has just been completed. Study of 0444 Gel in the Treatment of Inflammatory Lesions of Rosacea Sponsor: Nycomed US Inc …
October 8th, 2009, by Digital Davo | clinical trials
A trial seeking participants interested in being treated with topically disolved oxygen (TDO) has been posted to clinicaltrials.gov. Aria Aesthetics is listed as supplying the `Aria Regimens’ in 0.5%, and 0.25%. As the trial is double blind and placebo controlled, a third group will receive no TDO during their treatments. Zoe Draelos MD is listed as a contact for the trial. Dr. Draelos …
July 31st, 2009, by Digital Davo | clinical trials, doxium, laser therapy, pulse dye laser
A new trial is recruiting participants to evaluate the use of calcium dobelisate as a combination therapy, along with Pulse Dye Laser to treat the erythema, flushing and telangectasia associated with erythematotelangietatic rosacea. We know from rosacea and doxium that “Calcium dobesilate is a vasoactive drug with presumed effects on endothelial integrity, capillary permeability and blood viscosity.” Clinical Trial …
|
|
|
|
|
|